Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health Hepatitis A–D Testing Coverage | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentOscar HealthPolicy N/A

    Hepatitis Testing (A, B, C, D) Coverage Criteria

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and coverage criteria for laboratory testing for hepatitis A, B, C, and D for insured members, including screening, diagnostic, and monitoring indications and test-specific coverage statements.

    Policy Summary
    PayerOscar Health
    PolicyHepatitis Testing (A, B, C, D) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionCollect all samples needed for HCV diagnosis in a single visit and order reflex HCV RNA testing when the HCV antibody is reactive.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    HBsAg/anti-HBs/anti-HBc onceHBV testing recommended for adults ≥18
    HCV antibody onceHCV testing recommended for adults ≥18
    Every 3 monthsRepeat HCV antibody for ongoing risk
    Quantitative HAV/HDV NATNot covered
    660,000Estimated chronic HBV in US (2020)
    MultipleProcedure codes listed

    Coverage Criteria for Hepatitis A, B, C, and D Testing

    Hepatitis B - Covered Indications

    Covered HBV testing statements

    HBV - baseline adult screening: For all individuals 18 years of age and older, HBsAg, anti-HBs, and total anti-HBc testing once per lifetime meets criteriaage >= 18

    From policy statement

    HBV - annual screening for asymptomatic non-pregnant individuals

    • High-risk groups: Infants born to HBsAg-positive individuals; born in/traveled to regions with HBV prevalence >=2%; U.S.-born with parents from regions with HBV prevalence >=8%; history of incarceration; HIV infection; history of STI or multiple sex partners; men who have sex with men; household/needle-sharing/sex partners of HBV-infected individuals; injection-drug users; active or prior HCV infection; elevated liver enzymes; long-term hemodialysis; diabetes; healthcare/public safety workers exposed to blood/body fluids; receiving immunosuppressant therapy; receiving or about to begin PrEPone or more of listed risks
    Policy Summary
    PayerOscar Health
    PolicyHepatitis Testing (A, B, C, D) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionCollect all samples needed for HCV diagnosis in a single visit and order reflex HCV RNA testing when the HCV antibody is reactive.
    SourceLink
    On This Page
    Coverage Criteria for Hepatitis A, B, C, and D TestingProcedure and Billing CodesProvider Actions, Documentation, and Prior Authorization NotesBackground and EpidemiologyKey Definitions and AbbreviationsPolicy Revision History

    See policy list

    HBV - pregnancy: For pregnant individuals, HBsAg, anti-HBs, and anti-HBc testing for HBV meets criteriapregnancy

    From policy statement

    HBV - IgM follow-up: Individuals who test positive for total anti-HBc should have IgM anti-HBc testing to distinguish acute versus chronic infectionanti-HBc positive

    From policy statement

    HBV - post-vaccination seroconversion: Anti-HBs testing to confirm seroconversion after hepatitis B vaccination meets criteriapost-vaccination assessment

    From policy statement

    HBV - HBV DNA prior to immunosuppression: Individuals who test positive for HBV by initial antibody screening and who will undergo immunosuppressive drug therapy should have HBV DNA testingpre-immunosuppression

    From policy statement

    Hepatitis C - Covered Indications and Monitoring

    Covered HCV testing statements

    HCV - baseline adult screening: For all individuals 18 years of age and older, antibody testing for HCV infection once per lifetime meets criteriaage >= 18

    From policy statement

    HCV - post-exposure or one-time testing: One-time, post-exposure antibody testing meets criteria for recognized exposures or conditions (eg, illicit intranasal/injectable drug use; clotting factor before 1987; hemodialysis history; evidence of liver disease; HIV infection; organ transplant before July 1992; blood transfusion before July 1992; notification of exposure from donor; history of incarceration; unregulated tattoo; occupational exposures; perinatally exposed children; current sexual partners of HCV-infected persons)one-time after exposure/condition

    List from policy

    HCV - repeat screening for ongoing risk: Antibody testing for HCV once every three months meets criteria for individuals with ongoing risk factors while risk persists (current injection drug use with sharing, ongoing hemodialysis, high-risk sexual behavior)every 3 months while risk persists

    From policy statement

    HCV - pregnancy: For pregnant individuals, antibody testing for HCV meets criteria (test each pregnancy per guidance)pregnancy

    From policy statement and CDC/AASLD guidance

    HCV - qualitative NAT: Qualitative nucleic acid testing for HCV meets criteria as follow-up to a positive antibody screen to differentiate active versus resolved infection and for one-time screening of perinatally exposed infants aged 2–6 monthspost-antibody positive OR infant 2–6 months

    From policy statement and CDC recommendations

    HCV - immunocompromised: Qualitative NAT also meets criteria for immunocompromised individualsimmunocompromised

    From policy statement

    HCV - genotype prior to DAA: One-time HCV genotype testing prior to initiation of direct-acting antiviral therapy meets criteria to guide regimen selectionpre-DAA therapy

    From policy statement and AASLD recommendations

    HCV - viral load quantitative NAT: Quantitative nucleic acid testing for HCV viral load meets criteria prior to DAA therapy, after 4 weeks of therapy, at end of treatment, and at 12, 24, and 48 weeks post-treatmentspecified treatment timepoints

    From policy statement and AASLD monitoring guidance

    Hepatitis A - Covered Indications

    Covered HAV testing statements

    HAV - acute symptomatic testing: Individuals with signs and symptoms of acute viral hepatitis who have tested negative for HBV and HCV: testing for IgM anti-HAV or qualitative HAV RNA meets criteriasymptomatic and HBV/HCV negative

    From policy statement

    Hepatitis D - Covered Indications

    Covered HDV testing statements

    HDV - testing when HBV positive: Individuals who have tested positive for HBV (HBsAg positive): testing for anti-HDV or qualitative HDV RNA meets criteriaHBV positive

    From policy statement and WHO/EASL recommendations

    HCV Screening (CDC)

    Covered when meeting CDC screening recommendations

    Universal/targeted HCV screening: Hepatitis C screening at least once in a lifetime for all adults aged >=18 (except in settings where HCV RNA prevalence is <0.1%); one-time testing during each pregnancy (except where prevalence <0.1%); one-time testing regardless of age for people with recognized conditions or exposures; routine periodic testing for people with ongoing risk factorsprevalence <0.1% exception

    Includes specific exposure and risk groups listed by CDC

    HCV diagnostic algorithm

    Testing workflow requirements

    HCV diagnostic workflow: Initiate testing with an FDA-approved HCV antibody test with automatic reflex to NAT for HCV RNA if the antibody is reactive; collect all samples needed to permit single-visit diagnosis and order HCV RNA automatically when antibody is reactive; use NAT for diagnosis when exposure within prior 6 months regardless of antibody result

    CDC operational guidance and AASLD recommendations

    Perinatal HBV and adult HBV screening

    Perinatal and HBV testing recommendations

    Perinatally exposed infants HCV testing: Test all perinatally exposed infants for HCV RNA using NAT at 2–6 months; coordinate care with pediatric hepatitis C expertise if RNA detectable; infants with undetectable RNA do not require further follow-up unless clinically warranted2-6 months

    CDC guidance

    Adults HBV screening: Screen all adults aged >=18 at least once with the HBV triple panel (HBsAg, anti-HBs, total anti-HBc); offer HBV testing to anyone requesting it regardless of disclosed risk

    CDC recommendation

    Pregnant people HBV: Screen all pregnant people for HBsAg during each pregnancy, preferably in the first trimester, regardless of vaccination status or history of testing; if prior appropriately timed triple panel and no new exposures, only HBsAg may be needed

    CDC guidance

    Periodic testing for ongoing HCV risk

    Periodic testing for selected groups

    Periodic HCV testing: Routine periodic testing is recommended for people with ongoing risk factors (eg, current injectors who share equipment; people on maintenance hemodialysis); frequency per risk (eg, every 3 months antibody testing while risk persists) and per CDC/AASLD guidance

    Clinicians should consider repeat testing for individuals with ongoing risk behaviors

    Covered when meeting specialty/CDC/USPSTF guidance

    Selected specialty-society and USPSTF testing and follow-up recommendations (AASLD-IDSA, USPSTF) as summarized:

    HCV initial screening: One-time routine opt-out HCV antibody testing for all adults aged >=18 (AASLD-IDSA); USPSTF recommends screening adults 18–79 with anti-HCV followed by confirmatory PCR

    Reflex HCV RNA PCR recommended to establish active infection

    HCV testing indications beyond one-time: Periodic/annual testing for persons with ongoing risk (eg, people who inject drugs, HIV-infected MSM with unprotected sex, persons on PrEP); testing for suspected acute infection with HCV antibody and HCV RNA; quantitative HCV RNA prior to DAA and SVR12 testing 12+ weeks after therapy

    AASLD-IDSA recommendations

    HBV screening: Screen all adults >=18 at least once using the triple panel (HBsAg, anti-HBs, total anti-HBc); screen pregnant persons each pregnancy with HBsAg; screen persons at increased risk periodically while risk persists

    Triple panel identifies active infection, immunity, susceptibility, or resolved infection; use appropriate follow-up testing

    HAV testing: Test symptomatic patients suspected of acute HAV infection with IgM anti-HAV and/or HAV RNA; IgG anti-HAV indicates prior infection or vaccination and is not useful for acute diagnosis

    ALT and bilirubin can aid diagnosis; routine serology before vaccination not routinely recommended

    HDV testing: Test for HDV in persons with HBV infection when clinically indicated; use total anti-HDV for probable classification and HDV RNA for confirmation

    HDV testing important because coinfection accelerates disease progression

    Guideline-based screening, diagnostic, and monitoring criteria

    Covered clinically appropriate actions aligned with cited guidance when indicated by testing or clinical status

    Posttreatment monitoring after DAA failure: If patient fails DAA therapy and is not retreated or fails a subsequent DAA course, assess disease progression every 6–12 months with hepatic function panel, CBC, and INRevery 6–12 months

    AASLD recommendation

    HCC surveillance in cirrhosis: Patients with cirrhosis should undergo liver ultrasound, with or without AFP, every 6 months for hepatocellular carcinoma surveillanceevery 6 months

    AASLD guidance

    Pregnancy testing and monitoring for HCV: All pregnant individuals should be tested for HCV each pregnancy; HCV RNA and liver function tests are recommended for HCV-antibody-positive pregnant persons at initiation of prenatal caretest each pregnancy

    AASLD/AASLD-IDSA guidance

    Assessment of liver disease severity: Use noninvasive tests (serum biomarkers, transient elastography, imaging, routine labs) to estimate liver disease severity and diagnose cirrhosis; liver biopsy rarely requiredas clinically indicated

    AASLD background

    Testing of perinatally exposed children: All children born to individuals with acute or chronic HCV should be tested: antibody at/after 18 months; HCV RNA may be considered in first year and as early as 2 months; repetitive RNA testing prior to 18 months not recommended; confirm chronic infection with RNA after age 3 if antibody-positive after 18 monthsage-specific

    AASLD recommendations

    HCV testing approach (WHO): WHO recommends 2-step HCV screening: anti-HCV serology followed by HCV RNA NAT to confirm chronic infection and need for treatmenttwo-step testing

    WHO recommendation

    Population screening threshold (WHO): In settings with anti-HCV or HBsAg seroprevalence >=2% among the general population, routine access to and offering of serological testing to all adults/adolescents is recommended>= 2% seroprevalence

    WHO operational guidance

    HBV DNA testing for HBsAg-positive: After a positive HBsAg result, laboratory-based HBV DNA NAT (quantitative or qualitative) is recommended to assess viral load for treatment eligibility and to monitor response; point-of-care HBV DNA assays may be used where appropriateHBsAg positive

    WHO recommendation

    Reflex testing: Reflex HBV DNA testing and reflex anti-HDV antibody followed by HDV RNA where available are recommended strategies to promote linkage to carereflex testing where available

    WHO conditional recommendations

    Hepatitis D: testing criteria

    Covered/appropriate testing approaches per cited guidance:

    WHO preferred approach: For people with chronic hepatitis B (HBsAg positive), serological testing for anti-HDV antibodies may be performed for all individuals (preferred to scale up access and linkage to care)

    WHO conditional recommendation

    WHO prioritized groups if universal testing not feasible: Anti-HDV testing prioritized for HBsAg-positive people born in HDV-endemic areas, with advanced liver disease, receiving HBV treatment or with features suggesting HDV (low HBV DNA with high ALT), and persons with increased HDV risk (hemodialysis recipients, PLWH, people who inject drugs, sex workers, MSM)

    WHO conditional recommendation

    Reflex testing: Perform anti-HDV testing in HBsAg-positive individuals; if anti-HDV positive, perform HDV RNA NAT where available to detect active (viraemic) infection; reflex testing may be used to promote diagnosis

    WHO conditional recommendation; EASL strong recommendation to test anti-HDV at least once in all HBsAg-positive individuals and to test HDV RNA in all anti-HDV-positive individuals

    Hepatitis B: screening and evaluation

    HBV-related testing recommendations from AGA and EASL:

    Pre-immunosuppression screening: Screen for HBV (HBsAg and anti-HBc, followed by sensitive HBV DNA testing if positive) in patients at moderate or high risk who will undergo immunosuppressive drug therapy

    AGA strong recommendation; moderate-quality evidence

    Assess severity and contacts: Initial evaluation of chronic HBV should include history, physical, liver disease severity assessment (labs, imaging), HBV markers (HBsAg, anti-HBs, anti-HBc), and advise first-degree relatives/sexual partners to be tested and vaccinated if negative

    EASL recommendations

    Pregnancy screening: Screening for HBsAg in the first trimester of pregnancy is strongly recommended

    EASL evidence level 1, grade 1

    Hepatitis C: screening and monitoring

    HCV testing and monitoring recommendations:

    Confirming SVR: Confirm SVR by undetectable HCV RNA at 12 weeks after completion of all-oral DAA treatment; routine confirmation at 48 weeks post-treatment is recommended; periodic testing beyond 48 weeks only for patients with ongoing risk factors

    AGA guidance

    Screening populations: Screen adults 18+ at least once for HCV (IHS recommendation) and all pregnant persons during each pregnancy; screen people at higher risk more frequently

    IHS recommendations

    Use of rapid diagnostic tests: Rapid diagnostic tests using serum, plasma, fingerstick whole blood or saliva can be used instead of classical EIAs to facilitate anti-HCV antibody screening and improve access to care

    EASL recommendation

    Quantitative nucleic acid testing for hepatitis A virus (HAV) viral load DOES NOT MEET CRITERIA. For individuals with signs and symptoms of acute viral hepatitis who have tested negative for HBV and HCV, IgM anti-HAV serology or qualitative HAV RNA testing MEETS CRITERIA, but quantitative HAV NAT for viral load is not supported by this policy.

    Quantitative nucleic acid testing for hepatitis D virus (HDV) viral load DOES NOT MEET CRITERIA. Testing for anti-HDV antibody or qualitative HDV RNA MEETS CRITERIA for individuals who have tested positive for hepatitis B (HBsAg-positive), but quantitative HDV viral-load assays are not covered under this policy.

    Per CDC guidance, universal one-time hepatitis C screening for adults aged ≥18 and one-time testing in pregnancy are recommended except in settings where the prevalence of active HCV infection (HCV RNA positivity) is 0.1%. Settings with HCV RNA prevalence below this threshold are excluded from the universal one-time screening recommendation.

    Serologic testing for IgG anti-HAV or total anti-HAV (IgM+IgG combined) is not helpful for diagnosing acute hepatitis A. Only test for IgM anti-HAV in symptomatic patients when acute HAV infection is suspected; alternatively, qualitative HAV RNA testing can be used. Routine pre-vaccination serology is generally not recommended except in special circumstances.

    Repeat hepatitis C antibody testing in individuals with a prior positive HCV antibody test is not recommended. Repeat antibody testing adds cost without clinical benefit; instead, perform HCV viral-load (HCV RNA) testing to assess active versus resolved infection.

    If there is a conflict between this policy and any applicable government coverage policy (for example, Medicare Local Coverage Determinations or National Coverage Determinations, or state Medicaid rules), the applicable government policy will govern the determination. Providers should consult current LCD, NCD, and state Medicaid guidance when differences exist.

    Ordering repeat anti-HCV antibody testing in persons with previously positive HCV antibody results is discouraged. Use HCV RNA (viral load) testing to determine active infection rather than repeating antibody tests, which offer no additional clinical value.

    Procedure and Billing Codes

    Hepatitis D serologyCPTCovered
    86692Antibody; hepatitis, delta agent
    Serology and antigen detection (HBV, HAV, HCV)CPTCovered
    86704Hepatitis B core antibody (HBcAb); total
    86705Hepatitis B core antibody (HBcAb); IgM antibody
    86706Hepatitis B surface antibody (HBsAb)
    86708Hepatitis A antibody (HAAb)
    86709Hepatitis A antibody (HAAb), IgM antibody
    86803Hepatitis C antibody
    86804Hepatitis C antibody; confirmatory test (eg, immunoblot)
    87340Infectious agent antigen detection by immunoassay; hepatitis B surface antigen (HBsAg)
    87341Infectious agent antigen detection by immunoassay; HBsAg neutralization
    Nucleic acid testing and genotypeCPTCovered
    87380Infectious agent antigen detection by immunoassay; hepatitis, delta
    87516Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, amplified probe technique
    87517Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, quantification
    87520Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique
    87521Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe
    87522Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification
    87523Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription when performed
    87902Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus
    HCPCS/G-codes for HCV screeningHCPCSCovered
    G0472Hepatitis C antibody screening, for individual at high risk and other covered indication(s)
    G0567Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, screening, amplified probe technique
    Population seroprevalence threshold for routine testing
    Population seroprevalence thresholdRoutine offering of serologic testing recommended when anti-HCV or HBsAg seroprevalence in the general population is ≥ 2%
    Applies toAll adults and adolescents in settings meeting the ≥2% seroprevalence threshold (WHO operational guidance)
    Pregnancy considerationIn settings with ≥2% anti-HCV seroprevalence, HCV testing in pregnancy may be considered as part of general population testing

    Provider Actions, Documentation, and Prior Authorization Notes

    Prior Authorization

    Authorization depends on medical necessity and member benefits

    Coverage for hepatitis testing is subject to authorization and medical necessity and depends on the member’s benefit coverage at the time of the request; providers must ensure services meet authorization and medical necessity criteria before submitting claims.

    • Coverage does not guarantee reimbursement; services must meet authorization and medical necessity guidelines and member’s state of residence may affect determinations.
    • Providers are responsible for accurate documentation and appropriate coding per industry standards; failure may result in denial or recoupment.
    Prior Authorization

    Prior authorization — No prior authorization statements present

    No specific prior authorization program requirements or prior-authorization-only tests are stated in the policy excerpts provided.

    • The document enumerates procedure codes and guidance but does not list tests that universally require prior authorization in these sections.
    Prior Authorization

    HCV RNA and monitoring prior to/after therapy

    Quantitative HCV RNA testing is recommended prior to initiation of DAA therapy and quantitative HCV viral load testing is recommended 12+ weeks after completion of therapy to document sustained virologic response (SVR).

    • AASLD-IDSA: Quantitative HCV-RNA testing is recommended prior to initiation of antiviral therapy to document baseline viremia and 12+ weeks post-treatment to document SVR.
    • CDC/AASLD guidance supports reflex NAT (HCV RNA) following a reactive antibody test and collection of samples in a single visit to expedite diagnosis and treatment.
    Prior Authorization

    HBV DNA testing for treatment eligibility

    Laboratory-based HBV DNA NAT (quantitative or qualitative) is recommended after a positive HBsAg result to assess viral load for treatment eligibility and to monitor response; point-of-care HBV DNA assays may be used as an alternative where appropriate.

    • WHO/AASLD guidance: use HBV DNA testing following HBsAg+ to determine treatment eligibility and for monitoring.
    • Where available, reflex HBV DNA testing using an already-held sample or immediate collection after a positive HBsAg rapid test is an acceptable strategy.
    Billing Rule

    Procedure codes listed (prior auth may apply)

    The policy lists applicable CPT and HCPCS procedure codes for hepatitis testing; payers may require appropriate documentation or prior authorization per internal rules when these codes are billed.

    • Codes enumerated include CPT 86692, 86704–86709, 87340–87341, 87380, 87516–87523, 87902, and HCPCS G0472/G0567.
    • Providers should ensure supporting documentation aligns with the billed procedure codes to avoid denials.
    Prior Authorization

    Prior authorization — No requirements listed

    No prior authorization requirements are described in the provided chunks; the excerpts do not specify tests that require prior authorization.

    • The policy includes code lists and guidance but does not state specific prior-authorization rules in these sections.
    Documentation Required

    Submit accurate documentation and code claims per standard guidelines

    Providers must submit accurate documentation of services performed and code claims according to industry standard coding guidelines; noncompliance may result in claim denial or recoupment.

    • Follow industry coding guidelines (CPT, HCPCS, ICD-10, NCCI, CCI edits, CMS manuals) when submitting claims.
    • Oscar may deny or recoup payment if appropriate coding/billing guidelines or current reimbursement policies are not followed.
    Step Therapy

    Step therapy — Not specified in excerpt

    No step therapy requirements are described in the policy excerpts provided; the document does not impose a step-therapy sequence for hepatitis testing or treatment in these sections.

    • The policy notes clinical and guideline recommendations but does not prescribe stepwise treatment prerequisites in the provided text.
    Prior Authorization

    Therapy initiation requirements — baseline testing and prompt DAA start

    When acute HCV infection with quantifiable RNA is diagnosed, treatment should be initiated without awaiting spontaneous resolution; baseline quantitative HCV RNA and recommended baseline labs (CBC, INR, hepatic function panel, eGFR) should be documented within six months prior to DAA initiation.

    • AASLD-IDSA: After diagnosis of acute HCV with viremia, initiate treatment without waiting for spontaneous resolution.
    • Recommended pre-DAA labs within six months: CBC, INR, hepatic function panel, eGFR; quantitative HCV RNA and genotype testing prior to starting DAA as applicable.
    Step Therapy

    Monitoring after DAA failure — disease progression and HCC surveillance

    If patients fail DAA therapy and are not retreated (or fail subsequent DAA courses), assess disease progression every 6–12 months with hepatic function panel, CBC, and INR; patients with cirrhosis should undergo HCC surveillance every 6 months.

    • AASLD recommendation: disease progression assessment every 6–12 months for patients not retreated after DAA failure.
    • HCC surveillance with liver ultrasound ± AFP every 6 months for patients with cirrhosis.
    Step Therapy

    Reflex testing for HDV in HBsAg-positive individuals

    For HBsAg-positive individuals, perform anti-HDV testing and, if anti-HDV is positive, perform HDV RNA NAT where available; reflex anti-HDV followed by HDV RNA (where available) is an endorsed strategy to promote diagnosis and linkage to care.

    • WHO/EASL: perform anti-HDV in all HBsAg-positive individuals and test HDV RNA in anti-HDV-positive persons using standardised sensitive RT-PCR.
    • Reflex testing (anti-HDV then HDV RNA) may be used where available to improve diagnosis and linkage to care.
    Step Therapy

    Step therapy — None in publication/history sections

    No step therapy requirements are listed in the referenced publication and history sections of the policy.

    • Publication history and references do not include step-therapy mandates in the provided excerpts.
    Documentation Required

    Documentation and coding — document serology, NAT, and follow-up actions

    Providers should document serologic and nucleic acid test results and interpretive actions: record HBV triple-panel results and corresponding clinical actions (linkage to care, vaccination, counseling on reactivation), and document results of HBsAg, anti-HBc, HBeAg/anti-HBe, HBV DNA, anti-HDV, and HDV RNA when performed to support diagnosis and management.

    • Document HBV triple panel (HBsAg, anti-HBs, total anti-HBc) results and follow CDC interpretive actions.
    • Document HBV DNA testing and linkage-to-care steps when HBsAg is positive; document anti-HDV and HDV RNA results where testing performed.
    Documentation Required

    Sample collection and reflex testing documentation — single-visit collection and automatic reflex to NAT

    Clinicians should collect all samples needed to diagnose hepatitis C during a single visit and order HCV RNA testing automatically when the HCV antibody is reactive; documentation should support sample collection and reflex testing.

    • CDC operational guidance: collect samples to permit single-visit diagnosis and automatic reflex to NAT when antibody is reactive.
    • Automatic laboratory reflex to NAT streamlines diagnosis without additional patient or clinician action.
    Documentation Required

    HBV serology documentation — interpret results and record actions

    Document HBV serology test results and corresponding interpretive actions per the CDC serologic interpretation chart; when HBsAg is positive, document linkage to care, vaccination needs, counseling, and further testing plans.

    • Record test outcomes and actions (e.g., acute vs chronic infection, link to care, vaccination recommendations) based on HBsAg, anti-HBc, IgM anti-HBc, and anti-HBs results.
    • Follow CDC guidance for post-vaccination testing and counseling as documented.
    Documentation Required

    Pre-DAA therapy documentation — baseline labs and prior RNA/genotype

    Before initiating direct-acting antiviral therapy, document baseline laboratory tests (CBC, INR, hepatic function panel, eGFR) within six months and record prior quantitative HCV RNA and genotype testing when relevant to treatment selection.

    • Pre-DAA recommended labs include CBC, INR, hepatic function panel, and eGFR within six months prior to starting therapy.
    • Document quantitative HCV RNA and genotype results if used to guide regimen selection.
    Documentation Required

    HBV DNA testing/documentation — link to care and reflex testing where available

    When HBsAg is positive, document linkage-to-care activities and HBV DNA testing (laboratory or POC) and note consideration of reflex HBV DNA testing where available to assess viral load for treatment eligibility and monitoring.

    • Record whether HBV DNA testing was performed (quantitative/qualitative) and whether reflex HBV DNA was used to promote linkage to care.
    • Document any treatment decisions or monitoring plans informed by HBV DNA levels.
    Documentation Required

    Testing documentation — include serologic/NAT results and clinical context

    Document results of serologic and nucleic acid testing (HBsAg, anti-HBc, HBeAg/anti-HBe, HBV DNA, anti-HDV, HDV RNA) and relevant clinical indicators (aminotransferase flares, liver disease severity) to support diagnostic and management decisions.

    • Include clinical indicators such as aminotransferase elevations and assessments of liver disease severity alongside laboratory results.
    • Ensure documentation supports decisions for treatment, monitoring, and HCC surveillance where applicable.
    Note

    Publication history — policy dates and approval

    Publication history entry recorded: 06/16/2026 — Original Documentation; Governance Approved. Providers should note the policy effective date and last review when applying guidance.

    • Effective date: 10/01/2026; Last review: 06/16/2026.
    • Publication history confirms original documentation and governance approval on 06/16/2026.
    Denial Risk

    Coding and documentation compliance — denial risk for noncompliance

    Claims may be denied or recouped if coding, billing, or current reimbursement policies are not followed; ensure claims align with applicable government coverage (LCDs, NCDs, state Medicaid) where those take precedence.

    • Oscar may deny or recoup payment for inappropriate coding/billing.
    • If this policy conflicts with government coverage, the government policy governs determinations and may lead to denial if nonconcordant.
    Denial Risk

    Reflex NAT expectation — perform HCV RNA after reactive antibody

    Laboratories and clinicians are expected to perform reflex NAT (HCV RNA) testing after a reactive HCV antibody result in accordance with CDC operational guidance; failure to do so is inconsistent with CDC recommendations.

    • CDC: initiate HCV antibody testing with reflex to NAT for HCV RNA if antibody is reactive and collect samples to permit single-visit diagnosis.
    • Automatic laboratory reflex to NAT is recommended to reduce time to diagnosis and treatment initiation.
    Denial Risk

    HCV confirmatory testing — reflex RNA required to confirm active infection

    Failure to perform reflex HCV RNA PCR after a positive anti-HCV antibody may prevent confirmation of active infection and could affect linkage to care; HCV RNA testing is recommended to establish current infection.

    • AASLD-IDSA and CDC: HCV-antibody testing with reflex to HCV RNA PCR is recommended to establish active infection.
    • HCV RNA testing is recommended for suspected recent exposures regardless of antibody result.
    Denial Risk

    Repeat antibody testing discouraged — use viral load testing instead

    Ordering repeat HCV antibody testing in a person with a prior positive HCV test is discouraged; guidelines recommend HCV viral load testing instead and unnecessary repeat antibody testing may be considered low-value or denied.

    • AASLD: Repeat HCV antibody testing adds cost without clinical benefit; order HCV viral load testing to assess active versus resolved infection.
    • WHO/AASLD discourage repeat antibody testing when prior positive exists.
    Denial Risk

    Government policy precedence — follow LCD/NCD/state Medicaid rules

    If this policy conflicts with applicable government coverage (e.g., LCDs, NCDs, state Medicaid), the government policy will be used to make determinations; claims inconsistent with government policies may be denied.

    • Providers must follow applicable government coverage determinations where they take precedence over this policy.
    Denial Risk

    No denial triggers specified in references/publication-history

    Reference and publication-history sections do not specify denial triggers; no additional denial risks are identified in those sections of the policy.

    • Publication history and reference lists are informational and do not list procedural denial triggers.

    Background and Epidemiology

    Hepatitis A, B, C, and D are viral causes of liver inflammation with differing transmission modes and clinical courses. HAV is primarily transmitted by the fecal–oral route and typically causes an acute, self-limited hepatitis; diagnosis of acute HAV relies on IgM anti-HAV or qualitative HAV RNA. HBV is a DNA virus transmitted percutaneously, mucosal, or perinatal routes and can cause acute or chronic infection; initial evaluation commonly uses the HBV triple panel (HBsAg, anti-HBs, total anti-HBc) with HBV DNA NAT to assess viral load for treatment decisions. HCV is primarily bloodborne, often asymptomatic, and requires a two-step diagnostic approach: anti-HCV serology followed by HCV RNA NAT to confirm active infection and to guide treatment and monitoring (including quantitative HCV RNA at treatment timepoints). HDV requires HBV co-infection (HBsAg positive); testing strategies use anti-HDV for case finding and HDV RNA NAT for confirmation of viraemia where available. Chronic HBV and HCV infections can progress to cirrhosis and hepatocellular carcinoma, so appropriate screening, reflex testing, and linkage to care are essential.

    Key Definitions and Abbreviations

    HBsAg definition
    TermHBsAg (Hepatitis B surface antigen) — the surface antigen of hepatitis B virus used to identify active infection
    UsePart of the HBV triple panel to detect active infection
    Clinical actionPositive HBsAg prompts HBV DNA testing to assess viral load for treatment eligibility and monitoring
    anti-HBs definition
    Termanti-HBs (Hepatitis B surface antibody) — antibody indicating immunity to hepatitis B (from vaccination or prior infection)
    UseIncluded in HBV triple panel to determine immunity vs susceptibility
    Clinical actionNegative anti-HBs in susceptible persons indicates need for vaccination
    anti-HBc definition
    Termanti-HBc (Antibody to hepatitis B core antigen) — indicates prior or current exposure to HBV
    UseMeasured as part of the HBV triple panel to distinguish resolved infection from susceptibility
    Clinical actionA positive anti-HBc result should prompt IgM anti-HBc testing to distinguish acute from chronic infection when indicated
    NAT/NAAT definition
    TermNAT / NAAT — nucleic acid test (nucleic acid amplification test) for detection of viral RNA or DNA (e.g., HCV RNA)
    UseDetects active infection and quantifies viral load; used for confirmation after positive antibody tests and for monitoring therapy
    FormatsLaboratory-based RT-PCR assays and point-of-care molecular assays (examples: Molbio Truenat, Abbott RealTime, Cepheid Xpert)
    NAT (nucleic acid test) shorthand
    ShorthandNAT — commonly used abbreviation for nucleic acid test (detects/quantifies viral nucleic acid)
    ContextUsed interchangeably with NAAT in diagnostic and monitoring workflows for hepatitis viruses
    ExamplesIncludes qualitative and quantitative RT-PCR-based assays for HCV and HBV RNA/DNA
    SVR definition
    TermSVR (Sustained virologic response) — undetectable HCV RNA 12 weeks after completion of all-oral DAA therapy
    Confirmation timingConfirm SVR by undetectable HCV RNA at 12 weeks post-treatment; routine confirmation at 48 weeks is also recommended
    Clinical significanceSVR is a proxy for elimination of HCV RNA and treatment success
    HCV RNA (NAT) definition
    TermHCV RNA (NAT) — qualitative or quantitative nucleic acid tests that detect and quantify hepatitis C virus RNA to establish active infection
    UseUsed to confirm active infection after a reactive antibody test, to diagnose early infection, and to monitor response to therapy
    FormatsLaboratory RT-PCR assays and point-of-care HCV RNA assays (e.g., Cepheid Xpert) can be used depending on setting
    HBV triple panel definition
    TermHBV triple panel — concurrent testing for HBsAg, anti-HBs, and total anti-HBc
    PurposeIdentifies active infection, immunity from vaccination or past infection, susceptibility, or resolved infection
    RecommendationCDC recommends a triple panel for at least one-time adult screening to maximize diagnostic information
    HDV confirmed case definition
    Confirmed case definitionHDV confirmed case: detection of HDV RNA by nucleic acid test (qualitative, quantitative, or genotype testing) per CDC case classification
    Probable classificationReactive total anti-HDV (serology) constitutes a probable HDV case; RNA detection confirms active (viraemic) infection
    Clinical implicationHDV RNA testing is required for confirmation because antigen and IgM tests have limited specificity; HDV accelerates HBV progression
    Non-invasive methods (liver disease severity testing)
    TermNon-invasive methods — serum biomarkers, transient elastography, liver imaging, and routine blood tests used to estimate liver disease severity
    ComponentsRoutine labs (ALT, AST, albumin, bilirubin, INR, CBC/platelet count), serum fibrosis panels, transient elastography, ultrasound/CT
    RoleAccurate diagnosis of cirrhosis in most individuals; liver biopsy rarely required
    Two-step HCV testing (antibody then RNA)
    ApproachTwo-step HCV testing: perform anti-HCV serology first, then confirm active infection with HCV RNA NAT if antibody is positive
    Operational noteCollect samples needed for both steps in a single visit and reflex to NAT when antibody is reactive to avoid loss to follow-up
    WHO rationale~30% of infected persons spontaneously clear infection and remain antibody-positive but RNA-negative, necessitating NAT to confirm chronic infection
    HDV diagnosis definition
    DefinitionHDV diagnosis: high anti-HDV IgG/IgM on serology with confirmation by detection of HDV RNA in serum; WHO notes limited availability and lack of standardization for HDV RNA assays
    Testing strategyPerform anti-HDV testing in all HBsAg-positive individuals where feasible, and follow positive serology with HDV RNA NAT where available
    Practical noteReflex anti-HDV after HBsAg and reflex HDV RNA after anti-HDV may be used to promote diagnosis
    HBV evaluation (initial workup)
    Initial workupHBV evaluation should include history, physical exam, assessment of liver disease activity and severity, and HBV serologic markers (HBsAg, anti-HBs, anti-HBc)
    Further testingMeasurement of HBV DNA is essential for diagnosis, determining phase of infection, treatment decisions, and monitoring response; consider HBeAg/anti-HBe as appropriate
    Family/contact actionAdvise first-degree relatives and sexual partners of HBV-positive individuals to be tested and vaccinated if negative
    SVR (HCV) confirmation timing
    TimingSVR confirmation: undetectable HCV RNA at 12 weeks after completion of DAA therapy (SVR12)
    Extended confirmationRoutine confirmation at 48 weeks post-treatment is recommended; testing at 24 weeks may be considered individually
    Follow-upPeriodic testing beyond 48 weeks is reserved for patients with ongoing risk factors for reinfection
    AASLD-IDSA HCV guidance reference
    ReferenceAASLD-IDSA HCV guidance — recommendations for testing, managing, and treating hepatitis C (cited guidance documents used throughout the policy)
    Use in policyInforms recommendations for initial HCV testing, reflex NAT, monitoring during and after therapy, and special populations (pregnancy, perinatal testing)
    Key documentsAASLD-IDSA HCV guidance and related monitoring and management updates cited in references
    Point-of-care HCV RNA test definition
    TermPoint-of-care HCV RNA test — on-site molecular assays permitting rapid detection of HCV RNA (example: Cepheid Xpert® HCV)
    PerformanceCepheid Xpert HCV demonstrated high sensitivity (96.8%) and specificity (99.4%) with rapid results (~41 minutes) and is CLIA-waived/FDA-permitted for marketing
    RolePOC HCV RNA assays can be used alongside lab-based RNA assays to diagnose infection in decentralized settings and improve linkage to care

    Policy Revision History